The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Open accessAbstract
Purpose: Human epidermal growth factor receptor 2 ( HER2, ERBB2)–activating mutations occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial. Patients and Methods: Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. The primary end point was overall response rate using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A Simon two-stage optimal design was used. Other end points included progression-free survival and toxicity. HER2 testing was performed on tumor tissue by next generation sequencing, fluorescence in situ hybridization, immunohistochemistry, and protein mass spectrometry. Results: We treated 18 patients with advanced HER2-mutant lung adenocarcinomas. The median number of prior systemic therapies was two (range, zero to four prior therapies). The partial response rate was 44% (95% CI, 22% to 69%), meeting the primary end point. Responses were seen in patients with HER2 exon 20 insertions and point mutations in the kinase, transmembrane, and extracellular domains. Concurrent HER2 amplification was observed in two patients. HER2 immunohistochemistry ranged from 0 to 2+ and did not predict response, and responders had low HER2 protein expression measured by mass spectrometry. The median progression-free survival was 5 months (95% CI, 3 to 9 months). Toxicities included grade 1 or 2 infusion reactions, thrombocytopenia, and elevated hepatic transaminases. No patient stopped therapy as a result of toxicity or died on study. Conclusion: Ado-trastuzumab emtansine is an active agent in patients with HER2-mutant lung cancers. This is the first positive trial in this molecular subset of lung cancers. Further use and study of this agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“protein overexpression to elicit antitumor activity through inhibition of ligand-independent HER2 signaling, receptor internalization, and antibody-dependent cell-mediated cytotoxicity.(25,26) HER2 IHC 3+ or HER2 amplification by FISH is much rarer in lung tumors than in breast cancers (2% v 20%, respectively).”
BackgroundSelf-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 2×
“Kettering Cancer Center.(21) Patient characteristics are listed in Table 1.”
BackgroundSelf-citationTrastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“Indeed, the FDA has recently approved the use of vemurafenib in BRAF V600E–mutant Erdheim-Chester disease on the basis of results of 22 patients from a basket trial.(35,36) Multicenter collaboration is required to produce larger sample sizes(34,35) and adds to the strength of the applicability of results.”
BackgroundSelf-citationUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · cited 1×
“medical need with poorer survival than patients with other oncogenic drivers.(3,38) The current standard of care is chemotherapy, with pemetrexed providing the most benefit.”
BackgroundSelf-citationGainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Self-citationMazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668 · cited 1×
“higher response rates of up to 50% in patients with HER2-mutant lung cancers.(16,17) However, it is not”
BackgroundKrop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Wang, S. E., Narasanna, A., Perez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 470
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Self-citationDiamond, E. L., Subbiah, V., Lockhart, A. C., Blay, J.-Y., Puzanov, I., Chau, I., Raje, N. S., Wolf, J., Erinjeri, J. P., Torrisi, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5029 · Cited by 413
Self-citationGatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., & Hirsh, V. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh031 · Cited by 388
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
Self-citationMazières, J., Barlesi, F., Filleron, T., Besse, B., Monnet, I., Beau-Faller, M., Peters, S., Dansin, E., Früh, M., Pless, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv573 · Cited by 325
Sabari, J. K., Leonardi, G. C., Shu, C. A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy334 · Cited by 320
Self-citationHER2 amplification and HER2 mutation are distinct molecular targets in lung cancers
Li, B. T., Ross, D. S., Aisner, D. L., Chaft, J. E., Hsu, M., Kako, S. L., Kris, M. G., Varella-Garcia, M., & Arcila, M. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.025 · Cited by 286 · cited 2×
“suggest that HER2 mutation and amplification are largely separate therapeutic targets worthy of investigation in the laboratory and the clinic.(22,31) The fact that both mutations and amplifications of HER2 can be readily identified by NGS speaks for its clinical utility and huge potential for therapeutic discovery.”
BackgroundMethodGreulich, H., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K. E., Yun, C.-H., Zhang, X., Lee, S.-H., Cho, J., Ambrogio, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203201109 · Cited by 279
Peters, S., Stahel, R., Bubendorf, L., Bonomi, P., Villegas, A., Kowalski, D. M., Baik, C. S., Isla, D., Carpeno, J. D. C., Garrido, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 236
Langer, C. J., Stephenson, P., Thor, A., Vangel, M., & Johnson, D. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.105 · Cited by 224
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Pillai, R. N., Behera, M., Berry, L. D., Rossi, M. R., Kris, M. G., Johnson, B. E., Bunn, P. A., Ramalingam, S. S., & Khuri, F. R. (2017) · Cancer · doi:10.1002/cncr.30869 · Cited by 209
Self-citationA Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
Hotta, K., Aoe, K., Kozuki, T., Ohashi, K., Ninomiya, K., Ichihara, E., Kubo, T., Ninomiya, T., Chikamori, K., Harada, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.032 · Cited by 179
Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency
Cunanan, K. M., Gönen, M., Shen, R., Hyman, D. M., Riely, G. J., Begg, C. B., & Iasonos, A. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9751 · Cited by 136
Self-citationZinner, R., Glisson, B. S., Fossella, F. V., Pisters, K. M. W., Kies, M. S., Lee, P. M., Massarelli, E., Sabloff, B. S., Fritsche, H. A., Ro, J. Y., et al. (2003) · Lung Cancer · doi:10.1016/j.lungcan.2003.09.026 · Cited by 130
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2
Clamon, G. H., Herndon, J. E., Kern, J. A., Govindan, R., Garst, J. L., Watson, D. M., & Green, M. (2005) · Cancer · doi:10.1002/cncr.20950 · Cited by 115
Lara, P. N., Laptalo, L., Longmate, J., Lau, D. H., Gandour‐Edwards, R. F., Gumerlock, P. H., Doroshow, J. H., & Gandara, D. R. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.004 · Cited by 112
An efficient basket trial design
Cunanan, K. M., Iasonos, A. E., Shen, R., Begg, C. B., & Gönen, M. (2017) · Statistics in Medicine · doi:10.1002/sim.7227 · Cited by 112
Self-citationNuciforo, P. G., Thyparambil, S. P., Aura, C. M., Garrido-Castro, A. C., Vilaró, M., Peg, V., Jimenez, J., Vicario, R., Cecchi, F., Hoos, W. A., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.09.002 · Cited by 88
Self-citationKrug, L. M., Miller, V. A., Patel, J. D., Crapanzano, J. P., Azzoli, C. G., Gomez, J. E., Kris, M. G., Heelan, R. T., Pizzo, B., Tyson, L. B., et al. (2005) · Cancer · doi:10.1002/cncr.21428 · Cited by 84
Self-citationNSCLC and HER2: between lights and shadows
Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
Eng, J., Hsu, M., Chaft, J. E., Kris, M. G., Arcila, M. E., & Li, B. T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.030 · Cited by 54
Self-citationGandhi, L., Besse, B., Mazières, J., Waqar, S. N., Cortot, A. B., Barlési, F., Quoix, É., Otterson, G. A., Ettinger, D. S., Horn, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.398 · Cited by 53
Self-citationSerra, V., Vivancos, A. P., Puente, X. S., Felip, E., Silberschmidt, D., Caratù, G., Parra, J.-L., Mattos‐Arruda, L. D., Grueso, J., Hernández‐Losa, J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0132 · Cited by 49
Self-citationBesse, B., Soria, J., Yao, B., Kris, M. G., Chao, B. H., Cortot, A. B., Mazières, J., Socinski, M. A., Horn, L., Waqar, S. N., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu438.47 · Cited by 44
Self-citationHER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib
Li, B. T., Lee, A., O'Toole, S. A., Cooper, W., Yu, B., Chaft, J. E., Arcila, M. E., Kris, M. G., & Pavlakis, N. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.025 · Cited by 40
Self-citationSabari, J. K., Montecalvo, J., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.-C. V., Arbour, K. C., Shu, C. A., Hellmann, M. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.8512 · Cited by 39
Self-citationRapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer
Weiler, D., Diebold, J., Strobel, K., Aebi, S. P., & Gautschi, O. P. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000424 · Cited by 32
Stinchcombe, T. E., Stahel, R. A., Bubendorf, L., Bonomi, P., Villegas, A. E., Kowalski, D. M., Baik, C. S., Isla, D., Castro, J. D., Garrido, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.8509 · Cited by 31
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
“More recently, targeting HER2 mutation with adotrastuzumab emtansine (TDM-1) has shown promise with two cohorts demonstrating responses including mutants with no copy-number change [249].”
BackgroundNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Self-citationUnlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Metadata
- Authors
- Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., Cecchi, F., Schwartz, S., Pavlakis, N., Clarke, S., Won, H. H., Brzostowski, E. B., Riely, G. J., Solit, D. B., Hyman, D. M., Drilon, A., Rudin, C. M., Berger, M. F., Baselga, J., Scaltriti, M., Arcila, M. E., & Kris, M. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-08-20
- Volume
- 36
- Issue
- 24
- Pages
- 2532-2537
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2735084022
- Cited by
- 556
- References
- 42
- FWCI
- 41.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.